The pharmacological treatment of nystagmus: a review.
Nystagmus is an involuntary, to-and-fro movement of the eyes that can result in a reduction in visual acuity and oscillopsia. Mechanisms that cause nystagmus are better understood in some forms, such as acquired periodic alternating nystagmus, than in others, for example acquired pendular nystagmus, for which there is limited knowledge. Effective pharmacological treatment exists to reduce nystagmus, particularly in acquired nystagmus and, more recently, infantile nystagmus. However, as there are very few randomized controlled trials in the area, most pharmacological treatment options in nystagmus remain empirical.
McLean
Rebecca Jane
RJ
Ophthalmology Group, University of Leicester, Leicester LE27LX, UK.
Gottlob
Irene
I
D000588:Amines / Q000627:therapeutic use; D000818:Animals; D001418:Baclofen / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D020417:Nystagmus, Congenital / Q000188:drug therapy* / Q000503:physiopathology; D009759:Nystagmus, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D001418:Baclofen; D008559:Memantine